 |
text only |
|
|||||||||||||||||||||||||||||
Professional Profile
Research Interests: -Methods to improve the test for prostate cancer. -Identifying proteomic biomarkers for the early detection and monitoring of cancer. Honors and Achievements: -Award for outstanding achievement in Mathematics and Computer Science presented by Washington Academy of Sciences, 1996 Education: -Ph.D., Chemistry, University of Canterbury, Christchurch, New Zealand, 1975 -B.S., Chemistry, University of Canterbury, Christchurch, New Zealand, 1972 Professional Appointments: -Member, USA Mitchell Cancer Institute, 2002-present -Senior Investigator, National Institutes of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 1983-2002 -Forensic Toxicologist, Department of Scientific and Industrial Research, Christchurch, New Zealand, 1975-1983 Scientific Focus: Lewis Pannell, Ph.D., is Head of the Proteomics and Mass Spectrometry Laboratory at the USA Mitchell Cancer Institute. His research efforts are focused on the identification of biomarkers of cancer. Biomarkers allow for the “early detection” of cancerous cells which has become almost synonymous with prevention. Early detection and monitoring of cancer results in multiple alternative treatment options for the patient, as well as a much more hopeful prognosis. Two specific areas that Dr. Pannell’s research team is focused on are: 1) methods to improve the testing for prostate cancer and 2) new biomarkers for gynecological cancers. The biomarker PSA (prostate specific antigen) which is the current best indicator of prostate cancer, is not specific enough for reliable diagnosis because it is present at varying levels in healthy males. By looking closer for a more identifiable form of PSA, the test could be refined to provide the accuracy needed for true, reliable, early detection. The National Institutes of Health in Bethesda, Maryland are sponsoring this research effort. Dr. Pannell’s team is also looking for new biomarkers for the two most common gynecological cancers, ovarian and endometrial. Known as “silent killers” because of their lack of and /or vague symptoms in early stages Dr. Pannell’s lab is collaborating with the MCI’s two gynecological oncologists, Dr. Michael Finan and Dr. Rodney Rocconi, to not only identify the biomarkers but to identify a reliable method for obtaining cell samples. This bedside to bench research is highly dependent on patient cooperation, physician perseverance and solid science in the research lab. Current work has produced one hopeful new approach for which a patent has been filed. Further potential has also been identified in detecting women at risk for preeclampsia, preterm labor and infertility. Assisting other MCI researchers such as Dr. Lalita Shevde-Samant, Dr. Rajeev Samant and Dr.Rod Rocconi with their proteomic analyses, Dr. Pannell continues to be a part of melanoma and breast cancer research as well. A native of New Zealand, he enjoys a highly collaborative work environment and maintains many connections in cancer research as a result of having spent 19 years at the National Institutes of Health prior to joining the MCI. His largest outside collaboration is with Georgetown University in Washington DC, and is funded by the Department of Defense and NIH. Having worked in his specialty area for almost 35 years Dr. Pannell was the second member to join the MCI staff in 2002. However, his most impressive accomplishment is that he is a platelet donor for cancer patients with over 300 donations to date. Selected Publications: 1. Barsoum, A., Bainan, L., Rohrer, J., Coggin, Jr., J., Tucker, Al, Pannell, L., Schwarzenberger, P.: Production, Safety and Anti-Tumor Efficacy of recombinant Oncofetal Antigen/Immature Laminin Receptor Protein. Biomaterials 2009. 2. Mitra, A., Fillmore, R., Metge, B., Rajesh, M., Xi, Y., King, J., Ju, J., Pannell, L., Shevde, L.A., Samant, R.S.: Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Research, 10:R22, 2008. 3. Mbeunkui, F., Metge, B.J., Shevde, L.A., Pannell, L.K.:Identification Of Differentially Secreted Biomarkers Using LC-MS/MS in Isogenic Cell Lines Representing a Progression of Breast Cancer. J. Proteome Res.6(8): 2993-3002, 2007. 4. Mbeunkui, F., Fodstad, O., Pannell, L.K.: Secretory protein enrichment and analysis: an optimized approach applied on cancer cell lines using 2D LC-MS/MS. J. Proteome Res. 5(4): 899-906, 2006. 5. Tucker, A.M., Pannell, L.K., Wood, D.O.:Dissecting the Rickettsia prowazekii geonome: genetic and proteomic approaches. Ann. NY Acad. Sci. 1063: 35-46, 2005. 6. Baraniuk, J.N., Casado, B., Maibach, H., Cauw, D.J., Pannell, L.K., Hess, S.S.: A chronic fatigue syndrome–related proteome in human cerebrospinal fluid. BMC Neurol. 1(5): 22, 2005. Patents: -U.S. # 12/646,592. Novel Molecular Assay and uses Thereof. Filed 12/23/09 Active Grants: -Principal Investigator, NIH, (1R21CA122570-01A2), Profiling Urine Glycosylation of PSA and other Glyco-Biomarkers in Prostate Cancer, 2007-10 -Principal Investigator, NIH, (1R01DK073808-01A2), Protein Alterations in Skeletal Muscle Cells with Improved mtDNA repair, 2007-11 -Principal Investigator, DOD, (Baraniuk), Exercise-Induced Cerebrospinal Fluid Proteomic Biomarkers of Fatigue, 2009-12. |
||||
Lewis K. Pannell, Ph.D.University of South Alabama - Mobile Alabama 36688-0002 Appointments: Medical, Surgical and Gynecologic Oncology: (251) 665-8000 Radiation Oncology: (251) 445-9615 Administration: (251) 460-6993 For questions or comments Contact Us Date last changed: July 5, 2011 5:57 PM http://www.southalabama.edu/mci/pannell.html |
 |